TROPICACYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROPICACYL (TROPICACYL).
Tropicacyl contains tropicamide, a synthetic anticholinergic agent that blocks muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the iris sphincter muscle and ciliary muscle, producing mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation).
| Metabolism | Primarily metabolized by ester hydrolysis in plasma and liver; minor hepatic metabolism via CYP450 enzymes (CYP3A4 and CYP2D6). |
| Excretion | Renal: 60-80% (as unchanged drug and metabolites); fecal: 20-40% via biliary elimination |
| Half-life | Terminal half-life: 1.5-5 hours (clinically, ocular effects diminish rapidly within 4-6 hours due to redistribution) |
| Protein binding | Approximately 10-20% bound to plasma proteins (albumin) |
| Volume of Distribution | 0.6-1.2 L/kg; indicates distribution beyond plasma into total body water, with higher concentrations in ocular tissues |
| Bioavailability | Topical ophthalmic: approximately 1-2% due to limited corneal penetration and systemic absorption; oral/IV: not applicable for clinical use |
| Onset of Action | Topical ophthalmic: 15-30 minutes for cycloplegia; 5-10 minutes for mydriasis |
| Duration of Action | Cycloplegia: 2-6 hours; mydriasis: 4-8 hours; residual effects may last up to 24 hours in some patients |
| Molecular Weight | 284.35 Da |
1 to 2 drops of 0.5% or 1% solution to the eye(s) 15-20 minutes before examination; may repeat in 30 minutes if needed.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No clinically significant renal elimination; dose adjustment not required. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential systemic effects. |
| Pediatric use | Infants and children: 1 drop of 0.5% solution to each eye 15-20 minutes before examination; may repeat with 0.5% solution once after 15-20 minutes if needed. Max total dose: 1.5 mg per eye. |
| Geriatric use | Geriatric patients may be more susceptible to systemic anticholinergic effects; use lowest effective dose and monitor for adverse reactions. |
| 1st trimester | Avoid unless clearly needed; animal studies show embryocidal effects and fetal abnormalities with high doses. |
| 2nd trimester | Use only if potential benefit justifies risk to fetus; no well-controlled human studies. |
| 3rd trimester | Use only if potential benefit justifies risk; may cause neonatal anticholinergic effects if used near term. |
Clinical note
Comprehensive clinical and safety monograph for TROPICACYL (TROPICACYL).
| Placental transfer | Crosses placenta in animals; human data limited, but expected due to low molecular weight. |
| Breastfeeding | Minute amounts excreted in breast milk; unlikely to cause adverse effects in nursing infants. Caution with repeated high doses. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Common Effects | Stinging in the eyes Blurred vision Dryness in mouth |
| Serious Effects |
Hypersensitivity to tropicamide or any componentAngle-closure glaucoma or narrow anglesAcute ocular inflammationPosterior synechiae
| Precautions | Risk of increased intraocular pressure in patients with narrow-angle glaucoma, Systemic anticholinergic effects (tachycardia, dry mouth, blurred vision) especially in children and elderly, Photosensitivity due to prolonged mydriasis; advise sun protection, May cause confusion or exacerbation of psychosis in susceptible patients |
| Food/Dietary | No significant food interactions have been reported with ophthalmic tropicamide. However, alcohol may exacerbate the anticholinergic side effects such as dizziness and blurred vision. Maintain adequate hydration to reduce dry mouth. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Tropicacyl (tropicamide) is an anticholinergic agent. No well-controlled studies in pregnant women. Adequate animal reproduction studies have not been conducted. Risk cannot be ruled out. Use only if clearly needed. First trimester: Potential for anticholinergic effects; avoid if possible. Second and third trimesters: Limited data; no known teratogenicity reported. |
| Fetal Monitoring | Monitor for maternal systemic anticholinergic effects (tachycardia, dry mouth, blurred vision, urinary retention) and fetal heart rate changes if systemic absorption occurs. No specific fetal monitoring required with ophthalmic use. |
| Fertility Effects | No known effects on fertility from ophthalmic use. Systemic anticholinergic effects could theoretically impact fertility, but with ocular administration, systemic levels are low. |
| Clinical Pearls | Tropicacyl (tropicamide) is an anticholinergic mydriatic/cycloplegic agent used for diagnostic ophthalmoscopy. Onset of mydriasis occurs within 15-30 minutes; cycloplegia peaks at 30 minutes. Effects last 4-6 hours. Use the lowest effective dose (e.g., 0.5% for mydriasis, 1% for cycloplegia). Contraindicated in patients with narrow-angle glaucoma or those at risk for angle closure. Prolonged use may cause systemic anticholinergic effects (flushing, dry mouth, tachycardia, confusion) especially in children and elderly. Always assess anterior chamber depth before administration. Apply gentle pressure to nasolacrimal sac after instillation to minimize systemic absorption. |
| Patient Advice | Do not touch the dropper tip to any surface to avoid contamination. · After instillation, press gently on the inside corner of the eye (near the nose) for 1-2 minutes to reduce systemic absorption. · You may experience blurred vision and sensitivity to light (photophobia) for up to 6 hours; avoid driving or operating heavy machinery during this time. · Wear sunglasses to reduce discomfort from bright light. · Notify your doctor if you experience eye pain, redness, or vision changes after the effects wear off. · If you use contact lenses, remove them before instillation and wait at least 15 minutes before reinserting. · Keep out of reach of children. Overdose may cause rapid pulse, flushed skin, or confusion. |